From Lupin to Dr. Reddy's, year may end on a good note for pharma firms

The year is likely to end on a good note for Indian pharma companies as analysts expect an uptick in US sales. Around 13 -15 per cent year on year growth is expected in revenues primarily on the back of good product launches by firms like Lupin, Dr. Reddy's Laboratories etc. On the domestic front, too a 9-10 per cent growth is expected by most brokerages led by price growth as the long winter impacted volume growth here. 

During the previous quarter too, the Indian drug firms had reported a better than expected performance in the US. Foreign brokerage firm CLSA